Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G. and Bordignon, C., 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-3.

Anderson, W.F., Blaese, R.M. and Culver, K., 1990. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther 1, 331-62.

Andreadis, S.T., Roth, C.M., Le Doux, J.M., Morgan, J.R. and Yarmush, M.L., 1999. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 15, 1-11.

Baltimore, D., 1970. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226, 1209-11.

Barquinero, J., Eixarch, H. and Perez-Melgosa, M., 2004. Retroviral vectors: new applications for an old tool. Gene Ther 11 Suppl 1, S3-9.

Berns, A., 2004. Good news for gene therapy. N Engl J Med 350, 1679-80.

Bess, J.W., Jr., Gorelick, R.J., Bosche, W.J., Henderson, L.E. and Arthur, L.O., 1997. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230, 134-44.

Bishop, J.M., 1983. Cellular oncogenes and retroviruses. Annu Rev Biochem 52, 301-54.

Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L. and Fischer, A., 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-72.

CBER, 2001. Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther 12, 303-14.

Cladera, J., Martin, I. and O'Shea, P., 2001. The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface. Embo J 20, 19-26.

Cone, R.D. and Mulligan, R.C., 1984. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A 81, 6349-53.

Ellermann, V. and Bang, O., 1908. Experimentelle Leukämie bei Hühnern. Zentralbl. Bakteriol. Parasitenkd. Infectionskr. Hyg. Abt. Orig. 46, 595-609.

Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., Jakobsen, M.A., Christensen, H.O., Al Ghonaium, A., White, H.N., Smith, J.L., Levinsky, R.J., Ali, R.R., Kinnon, C. and Thrasher, A.J., 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-7.

Gluschankof, P., Mondor, I., Gelderblom, H.R. and Sattentau, Q.J., 1997. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230, 125-33.

Guibinga, G.H., Miyanohara, A., Esko, J.D. and Friedmann, T., 2002. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 5, 538-46.

Gunzburg, W.H., 2003. Retroviral gene therapy--where now? Trends Mol Med 9, 277-8.

Huebner, R.J. and Todaro, G.J., 1969. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci U S A 64, 1087-94.

Katane, M., Takao, E., Kubo, Y., Fujita, R. and Amanuma, H., 2002. Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein. EMBO Rep 3, 899-904.

Kotani, H., Newton, P.B., 3rd, Zhang, S., Chiang, Y.L., Otto, E., Weaver, L., Blaese, R.M., Anderson, W.F. and McGarrity, G.J., 1994. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 5, 19-28.

Kuiper, M., Sanches, R.M., Walford, J.A. and Slater, N.K., 2002. Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol Bioeng 80, 445-53.

Makino, M., Ishikawa, G., Yamaguchi, K., Okada, Y., Watanabe, K., Sasaki-Iwaki, Y., Manabe, S., Honda, M. and Komuro, K., 1994. Concentration of live retrovirus with a regenerated cellulose hollow fiber, BMM. Arch Virol 139, 87-96.

Mann, R., Mulligan, R.C. and Baltimore, D., 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153-9.

McTaggart, S. and Al-Rubeai, M., 2002. Retroviral vectors for human gene delivery. Biotechnol Adv 20, 1-31.

Merten, O.W., 2004. State-of-the-art of the production of retroviral vectors. J Gene Med 6 Suppl 1, S105-24.

Miller, A.D., 1997. Development and applications of retroviral vectors. Cold Spring Harbor Laboratory Press, New York.

Moloney, J.B., 1960. Biological studies on a lymphoid-leukemia virus extracted from sarcoma 37. I. Origin and introductory investigations. J Natl Cancer Inst 24, 933-51.

Mondor, I., Ugolini, S. and Sattentau, Q.J., 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 72, 3623-34.

Niiyama, Y., Igarashi, K., Tsukamoto, K., Kurokawa, T. and Sugino, Y., 1975. Biochemical studies on bovine adenovirus type 3. I. Purification and properties. J Virol 16, 621-33.

Ott, D.E., 1997. Cellular proteins in HIV virions. Rev Med Virol 7, 167-180.

Ott, D.E., 2002. Potential roles of cellular proteins in HIV-1. Rev Med Virol 12, 359-74.

Palù, G., Parolin, C., Takeuchi, Y. and Pizzato, M., 2000. Progress with retroviral gene vectors. Rev Med Virol 10, 185-202.

Paul, R.W., Morris, D., Hess, B.W., Dunn, J. and Overell, R.W., 1993. Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther 4, 609-15.

Pizzato, M., Blair, E.D., Fling, M., Kopf, J., Tomassetti, A., Weiss, R.A. and Takeuchi, Y., 2001. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther 8, 1088-96.

Rainov, N.G. and Ren, H., 2003. Clinical trials with retrovirus mediated gene therapy--what have we learned? J Neurooncol 65, 227-36.

Roderiquez, G., Oravecz, T., Yanagishita, M., Bou-Habib, D.C., Mostowski, H. and Norcross, M.A., 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 69, 2233-9.

Rous, P., 1911. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397-411.

Shimotohno, K. and Temin, H.M., 1981. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26, 67-77.

Sinn, P.L., Sauter, S.L. and McCray, P.B., Jr., 2005. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 12, 1089-98.

Skalka, A.M. and Goff, S.P., 1993. Reverse transcriptase. Cold Spring Harbor Laboratory Press, New York.

Slepushkin, V., Chang, N., Cohen, R., Gan, Y., Jiang, B., Deausen, E., Berlinger, D., Binder, G., Andre, K., Humeau, L. and Drupolic, B., 2003. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocessing J 2, 89-95.

Tai, C.K., Logg, C.R., Park, J.M., Anderson, W.F., Press, M.F. and Kasahara, N., 2003. Antibody-mediated targeting of replication-competent retroviral vectors. Hum Gene Ther 14, 789-802.

Temin, H.M. and Mizutani, S., 1970. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226, 1211-3.

Trubey, C.M., Chertova, E., Coren, L.V., Hilburn, J.M., Hixson, C.V., Nagashima, K., Lifson, J.D. and Ott, D.E., 2003. Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J Virol 77, 12699-709.

Varmus, H.E., 1984. The molecular genetics of cellular oncogenes. Annu Rev Genet 18, 553-612.

Vellekamp, G., Porter, F.W., Sutjipto, S., Cutler, C., Bondoc, L., Liu, Y.H., Wylie, D., Cannon-Carlson, S., Tang, J.T., Frei, A., Voloch, M. and Zhuang, S., 2001. Empty capsids in column-purified recombinant adenovirus preparations. Hum Gene Ther 12, 1923-36.

Vives, R.R., Imberty, A., Sattentau, Q.J. and Lortat-Jacob, H., 2005. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280, 21353-7.

Vogt, V.M., 1997. Retroviral virions and genomes. Cold Spring Harbor Laboratory Press, New York.

Watanabe, S. and Temin, H.M., 1983. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol 3, 2241-9.

Wei, C.M., Gibson, M., Spear, P.G. and Scolnick, E.M., 1981. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol 39, 935-44.

Williams, S.L., Nesbeth, D., Darling, D.C., Farzaneh, F. and Slater, N.K., 2005. Affinity recovery of Moloney Murine Leukaemia Virus. J Chromatogr B Analyt Technol Biomed Life Sci 820, 111-9.

Ye, K., Jin, S., Ataai, M.M., Schultz, J.S. and Ibeh, J., 2004. Tagging retrovirus vectors with a metal binding peptide and one-step purification by immobilized metal affinity chromatography. J Virol 78, 9820-7.